AVIR Share Price Performance
US$5.67
2.73 (92.86%)
46.0% undervalued intrinsic discount
US$10.50
Fair Value
Price US$5.67
AnalystHighTarget US$10.50
AnalystConsensusTarget US$7.67
Fair ValueUS$10.50
Share Pricen/a
Atea Pharmaceuticals, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
AVIR Community Narratives
AN
Fair Value US$10.5 46.0% undervalued intrinsic discount
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7.67 26.0% undervalued intrinsic discount
Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$10.5
46.0% undervalued intrinsic discount
Fair Value
Profit Margin
20.06%
Future PE
25.69x
Price in 2029
US$0
Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biotechnology company focused on developing oral direct acting antivirals for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$7.67
26.0% undervalued intrinsic discount
Fair Value
Profit Margin
21.47%
Future PE
43.57x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Fair Value: US$10.5 46.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Fair Value: US$7.67 26.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Atea Pharmaceuticals, Inc. Key Details
About AVIR
- Founded
- 2012
- Employees
- 55
- CEO
- WebsiteView website
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Recent AVIR News & Updates
